Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

‘Trojan horse’ antibiotic shows promise
"Our results support cefiderocol as a novel approach that might be used to overcome Gram-negative resistance." (Stock photo)
Drug works by tricking bacteria in allowing it to enter 

A new antibiotic that acts like the Trojan horse in Greek legend has shown promise in phase two trials, scientists have said.

Cefiderocol works by tricking bacteria in allowing it to enter. It was found to be as effective as the current standard-of-care antibiotic, in the treatment of complicated urinary tract infections (UTIs) caused by several multi-drug-resistant Gram-negative bacteria.

Findings published in The Lancet Infectious Diseases journal suggest that patients treated with cefiderocol had a higher and more sustained level of pathogen eradication; and similar clinical outcomes to those treated with imipenem-cilastatin.

The study randomised 448 adults who had been hospitalised with a complicated UTI or uncomplicated pyelonephritis. Three hundred patients received three daily infusions of cefiderocol for seven to 10 days, while the remainder were given imipenem-cilastatin.

Seven days after treatment stopped, cefiderocol showed efficacy rates of 73 per cent and 55 per cent respectively for clinical and microbiological responses.

Lead author Dr Simon Portsmouth, from Shionogi Inc, said: "Cefiderocol was found to be both safe and tolerable in a population of older patients who were very ill with complex comorbid conditions and a wide range of multidrug-resistant pathogens. Our results support cefiderocol as a novel approach that might be used to overcome Gram-negative resistance.

"Ongoing clinical trials of pneumonia, including hospital-acquired pneumonia and ventilator-associated pneumonia, and a study in patients with carbapenem-resistant infections, will provide additional important information about cefiderocol."

Become a member or log in to add this story to your CPD history

FIVP publishes CMA Compliance Checklist

News Story 1
 FIVP has published a CMA Compliance Checklist to support independent practices with the Market Investigation Order.

The document includes deadlines for small and large businesses, with tick boxes for each of the tasks. The organisation also invites practices to contact them for support with requirements.

Rita Dingwall, FIVP chair, said: FIVP appreciates that navigating the new CMA requirements can feel daunting. We hope this checklist will make things a little easier, helping independent practices work through what is required with confidence. 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.